ARVN Stock Price, Chart, Stats & News
ARVN chart
Fundamentals
Gross margin | 99.54% |
Operating margin | -44.02% |
Pretax margin | -30.62% |
Net margin | -30.77% |
Effective tax rate | -0.50% |
ROA | -11.26% |
ROE | -14.25% |
D/E | 0.02x |
Interest coverage ratio | – |
ARVN valuation
P/E | – |
P/S | 2.47x |
P/B | 1.51x |
P/CF | -2.39x |
P/FCF | -2.35x |
P/OCF | -2.39x |
PEG | 0.16x |
EV multiple | -8.04x |
About
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F.
Similar securities
Based on sector and market capitalization
